51. Natural history of indolent-anti-synthetase syndrome-associated interstitial lung disease.
- Author
-
Moda M, Sumikawa H, Shintani R, Takeuchi N, Kagawa T, Takimoto T, and Arai T
- Subjects
- Humans, Male, Female, Retrospective Studies, Middle Aged, Aged, Vital Capacity, Mucin-1 blood, Risk Factors, Myositis complications, Lung Diseases, Interstitial etiology, Disease Progression, Tomography, X-Ray Computed
- Abstract
Background: Anti-synthetase syndrome-associated interstitial lung disease (ASS-ILD) may occur without myositis. Although a recent Japanese guide proposed a watch-and-wait approach for chronic ASS-ILD without obvious progression, the natural history of this subgroup and the appropriateness of the watch-and-wait approach remain unclear. We aimed to describe the natural history of ASS-ILD, that is sufficiently indolent to be a candidate for the watch-and-wait approach., Methods: Among consecutive patients with ASS-ILD, we retrospectively identified those without myositis, acute/subacute onset, and significant lung function impairment, which qualified them as indolent-ASS-ILD cases, and described their natural course. Additionally, we evaluated the risk factors for fibrosis progression on computed tomography (CT) using the Cox proportional hazards model., Results: Among 80 patients with ASS-ILD, we identified 33 with indolent-ASS-ILD, all of whom were initially followed up with a watch-and-wait approach. Among 30 patients with sufficient follow-up data, 27 (90%) showed a stable course without treatment over 24 months. Subsequently, four patients experienced ≥10% relative forced vital capacity (FVC) decline without treatment during a median follow-up duration of 81 months. Seven patients showed fibrosis progression with >10% increase in the total lung area on CT. Higher levels of Krebs von den Lungen-6 (KL-6) and surfactant protein-D (SP-D) were associated with fibrosis progression on CT., Conclusion: Most patients with indolent-ASS-ILD did not experience ≥10% relative FVC decline over five years without treatment. However, fibrosis progression on CT, which seemed to precede significant FVC decline, occurred more frequently, especially in patients with higher KL-6 and SP-D levels., Competing Interests: Declaration of competing interest Mitsuhiro Moda has no conflict of interest; Hiromitsu Sumikawa has no conflict of interest; Ryota Shintani has no conflict of interest; Naoko Takeuchi has no conflict of interest; Tomoko Kagawa has no conflict of interest; Takayuki Takimoto has no conflict of interest; Toru Arai received lecture fees from Boehringer Ingelheim and Shionogi for activities not connected to the submitted work., (Copyright © 2024 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF